NGEN

NervGen Pharma is a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic disorders. Its lead asset, NVG-291, is a peptide candidate designed to promote nervous system repair by targeting the inhibitory biology associated with chondroitin sulfate proteoglycans through protein tyrosine phosphatase sigma. The company is running the Phase 1b/2a CONNECT SCI study in spinal cord injury and has reported positive chronic cohort topline data while preparing for a Phase 3 program. NervGen is also advancing a next-generation candidate, NVG-300, in preclinical studies for ischemic stroke, amyotrophic lateral sclerosis, and spinal cord injury. The company licenses core technology from Case Western Reserve University and is publicly traded on Nasdaq.